<VariationArchive VariationID="3245109" VariationName="NC_000009.11:g.(?_137713923)_(137717770_?)del" VariationType="Deletion" Accession="VCV003245109" Version="1" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-07-07" DateCreated="2024-06-30" MostRecentSubmission="2024-06-29">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="3406354" VariationID="3245109">
      <GeneList>
        <Gene Symbol="COL5A1" FullName="collagen type V alpha 1 chain" GeneID="1289" HGNC_ID="HGNC:2209" Source="calculated" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>9q34.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="9" Accession="NC_000009.12" start="134641803" stop="134844843" display_start="134641803" display_stop="134844843" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="9" Accession="NC_000009.11" start="137533651" stop="137736688" display_start="137533651" display_stop="137736688" Strand="+" />
          </Location>
          <OMIM>120215</OMIM>
          <Haploinsufficiency last_evaluated="2017-12-14" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=COL5A1">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2017-12-14" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=COL5A1">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NC_000009.11:g.(?_137713923)_(137717770_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>9q34.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="9" Accession="NC_000009.11" innerStart="137713923" innerStop="137717770" display_start="137713923" display_stop="137717770" variantLength="3848" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000009.11" sequenceAccession="NC_000009" sequenceVersion="11" change="g.(?_137713923)_(137717770_?)del" Assembly="GRCh37">
            <Expression>NC_000009.11:g.(?_137713923)_(137717770_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000009.11:g.(?_137713923)_(137717770_?)del AND Ehlers-Danlos syndrome, classic type, 1" Accession="RCV004581877" Version="1">
        <ClassifiedConditionList TraitSetID="56939">
          <ClassifiedCondition DB="MedGen" ID="C0268335">Ehlers-Danlos syndrome, classic type, 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-08-06" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-08-06" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2024-06-30" MostRecentSubmission="2024-06-29">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">19344236</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22696272</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23587214</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">7695699</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8218237</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="56939" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="54525" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">EDS I</ElementValue>
                <XRef Type="MIM" ID="130000" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ehlers-Danlos syndrome, type 1</ElementValue>
                <XRef ID="Ehlers-Danlos+Syndrome+Classic+Type/2484" DB="Genetic Alliance" />
                <XRef ID="83470009" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Ehlers-Danlos syndrome, classic type, 1</ElementValue>
                <XRef ID="MONDO:0019567" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">EHLERS-DANLOS SYNDROME, GRAVIS TYPE</ElementValue>
                <XRef Type="MIM" ID="130000" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">EHLERS-DANLOS SYNDROME, SEVERE CLASSIC TYPE</ElementValue>
                <XRef Type="MIM" ID="130000" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ehlers-Danlos syndrome, classic type I</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">EDSCL1</ElementValue>
                <XRef Type="MIM" ID="130000" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">cEDS</ElementValue>
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">EDS1</ElementValue>
                <XRef Type="MIM" ID="130000" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Classic Ehlers-Danlos syndrome (cEDS) is a connective tissue disorder characterized by skin hyperextensibility, atrophic scarring, and generalized joint hypermobility (GJH). The skin is soft and doughy to the touch, and hyperextensible, extending easily and snapping back after release (unlike lax, redundant skin, as in cutis laxa). The skin is fragile, as manifested by splitting of the dermis following relatively minor trauma, especially over pressure points (knees, elbows) and areas prone to trauma (shins, forehead, chin). Wound healing is poor, and stretching of scars after apparently successful primary wound healing is characteristic. Complications of joint hypermobility, such as dislocations of the shoulder, patella, digits, hip, radius, and clavicle, usually resolve spontaneously or are easily managed by the affected individual. Other features include hypotonia with delayed motor development, fatigue and muscle cramps, and easy bruising. Mitral valve prolapse can occur infrequently, but tends to be of little clinical consequence. Aortic root dilatation has been reported, appears to be more common in young individuals, and rarely progresses.</Attribute>
                <XRef ID="NBK1244" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301422</ID>
                <ID Source="BookShelf">NBK1244</ID>
              </Citation>
              <XRef ID="C0268335" DB="MedGen" />
              <XRef ID="MONDO:0019567" DB="MONDO" />
              <XRef Type="MIM" ID="130000" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="9835627" SubmissionDate="2024-06-04" DateLastUpdated="2024-06-29" DateCreated="2024-06-29">
        <ClinVarSubmissionID localKey="NC_000009.11:g.(?_137713923)_(137717770_?)del|MedGen:C0268335" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV005067218" DateUpdated="2024-06-29" DateCreated="2024-06-29" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-08-06">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">7695699</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">8218237</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">19344236</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22696272</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23587214</ID>
          </Citation>
          <Comment>This variant has not been reported in the literature in individuals affected with COL5A1-related conditions. This variant is a gross deletion of the genomic region encompassing exon(s) 59-63 of the COL5A1 gene. This variant would be expected to be in-frame, preserving the integrity of the reading frame. This variant disrupts the triple helix domain of COL5A1. Glycine residues within the Gly-Xaa-Yaa repeats of the triple helix domain are required for the structure and stability of fibrillar collagens (PMID: 7695699, 8218237, 19344236), and variants at these glycine residues in COL5A1 are more frequently observed in individuals with disease than in the general population (PMID: 22696272, 23587214). However, the clinical significance of this observation remains uncertain since only a limited number of affected individuals have been described to date. This variant disrupts a region of the COL5A1 protein in which other variant(s) (p.Cys1671Tyr) have been determined to be pathogenic (Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
              <MethodAttribute>
                <Attribute Type="StructVarMethodType">Read depth</Attribute>
              </MethodAttribute>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000009.11:g.(?_137713923)_(137717770_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0268335" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14505471</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="9835627" TraitType="Disease" MappingType="XRef" MappingValue="C0268335" MappingRef="MedGen">
        <MedGen CUI="C0268335" Name="Ehlers-Danlos syndrome, classic type, 1" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

